复宏汉霖(02696.HK)单抗注射液汉斯状获欧盟批准上市

阿斯达克财经
06 Feb

复宏汉霖(02696.HK) 公布,近日,欧盟委员会“EC”已批准公司自主研发的创新抗PD-1单抗斯鲁利单抗注射液(境内商品名:汉斯状)联合卡铂和依托泊苷适用于广泛期小细胞肺癌成人患者的一线治疗,其于欧盟获批的商品名为Hetronifly。此次获批意味汉斯状在所有欧盟成员国及冰岛、列支敦士登和挪威获得集中上市许可。
据此,汉斯状成为公司第二个于欧盟获批上市的产品,也成为欧盟首个批准用于广泛期小细胞肺癌治疗的抗PD-1单抗药品。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10